Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone + AC versus docetaxel + AC as neoadjuvant therapy for HER2-negative high-risk early or locally advanced breast cancer
CTR20223015Phase 3Active
- Sponsor
- 成都华昊中天药业有限公司
- Start
- May 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of utidelone, docetaxel, doxorubicin, cyclophosphamide in breast cancer, sponsored by 成都华昊中天药业有限公司. Started May 2023; status: active.
02
Drugs
utidelonedocetaxeldoxorubicincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20223015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223015.